Please assess the completion status of the following clinical trial:

Trial Title: S-1 Plus Oxaliplatin Compared With Fluorouracil, Leucovorin Calcium Plus Oxaliplatin as Perioperative Chemotherapy for Advanced Gastric Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed gastric adenocarcinoma,diagnosed as locally advanced gastric cancer and primary tumor invades or penetrates serosa~* Ambulatory males or females, aged 18-80 years old~* ECOG score 0-2~* Given informed consent~* Life expectancy more than 3 months~* Measurable lesion~* Normal cardiac, hepatic, renal, and bone marrow function(WBC:3.5×10\^9/l\~12×10\^9/l;PLT:\>100×109/l;Bil:\<1.5 fold of upper limit value; ALT/AST:\<2.5 fold of upper limit value;Ccr:\>80ml/min;Cr:1.5mg/dl)~Exclusion Criteria:~* Prior stomach surgery~* Previous cytotoxic chemotherapy, radiotherapy, target therapy or immunotherapy for any tumor~* History of another malignancy except cured basal cell carcinoma of skin and cured carcinoma in-situ of uterine cervix~* distant metastasis(such as No.16 and No.13 lymphnode,liver, lung,brain,bones or peritoneal metastasis)~* Severe bleeding~* Bowel obstruction, ileus or complete pyloric obstruction~* Serious uncontrolled concomitant disease~* History of myocardial infarction in 6 months~* Woman with on-going pregnancy or breast-feeding, or contemplating pregnancy~* Systemic treatment with corticosteroid~* Patients judged inappropriate for the trial by the physicians

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- FOLFOX (Type: ACTIVE_COMPARATOR): None
- SOX (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).